References
1 中华人民共和国国家卫生健康委员会法规司. 关于发布《输血相容性检测标准》等3项推荐性卫生行业标准的通告: 国卫通〔2022〕1号[EB/OL]. (2022-02-23)[2022-09-01]. http://www.nhc.gov.cn/fzs/s7852d/202202/1484f47dcf824ee8bae3ad7b6809e603.shtml.
2 Avery RK, Adal KA, Longworth DL, et al. A survey of allogeneic bone marrow transplant programs in the United States regarding Cytomegalovirus prophylaxis and pre-emptive therapy[J]. Bone Marrow Transplant, 2000, 26(7): 763-767. PMID: 11042658. DOI: 10.1038/sj.bmt.1702608.
3 Lightdale JR, Randolph AG, Tran CM, et al. Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2012, 18(5): 813-817. PMID: 22080050. DOI: 10.1016/j.bbmt.2011.10.043.
4 Tay J, Allan DS, Chatelain E, et al. Liberal versus restrictive red blood cell transfusion thresholds in hematopoietic cell transplantation: a randomized, open label, phase III, noninferiority trial[J]. J Clin Oncol, 2020, 38(13): 1463-1473. PMID: 32083994. DOI: 10.1200/JCO.19.01836.
5 McPherson ME, Anderson AR, Haight AE, et al. Transfusion management of sickle cell patients during bone marrow transplantation with matched sibling donor[J]. Transfusion, 2009, 49(9): 1977-1986. PMID: 19453984. DOI: 10.1111/j.1537-2995.2009.02213.x.
6 Crighton GL, Estcourt LJ, Wood EM, et al. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]. Cochrane Database Syst Rev, 2015, 2015(9): CD010981. PMID: 26422767. PMCID: PMC4610062. DOI: 10.1002/14651858.CD010981.pub2.
7 Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study[J]. Lancet, 2012, 380(9850): 1309-1316. PMID: 22877506. DOI: 10.1016/S0140-6736(12)60689-8.
8 Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers[J]. N Engl J Med, 2013, 368(19): 1771-1780. PMID: 23656642. DOI: 10.1056/NEJMoa1212772.
9 Stanworth SJ, Estcourt LJ, Llewelyn CA, et al. Impact of prophylactic platelet transfusions on bleeding events in patients with hematologic malignancies: a subgroup analysis of a randomized trial[J]. Transfusion, 2014, 54(10): 2385-2393. PMID: 24724863. DOI: 10.1111/trf.12646.
10 Estcourt LJ, Stanworth SJ, Doree C, et al. Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation[J]. Cochrane Database Syst Rev, 2015, 2015(11): CD010983. PMID: 26576687. PMCID: PMC4717525. DOI: 10.1002/14651858.CD010983.pub2.
11 Cohn CS, Delaney M, Johnson ST, et al. Technical Manual[M]. 20th ed. Bethesda: American Association of Blood Banks, 2020.
12 Meyer SC, O'Meara A, Buser AS, et al. Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2013, 19(3): 440-444. PMID: 23089566. DOI: 10.1016/j.bbmt.2012.10.012.
13 Pullarkat V, Blanchard S, Tegtmeier B, et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation[J]. Bone Marrow Transplant, 2008, 42(12): 799-805. PMID: 18762767. DOI: 10.1038/bmt.2008.262.
14 Maradei SC, Maiolino A, de Azevedo AM, et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation[J]. Blood, 2009, 114(6): 1270-1275. PMID: 19401560. DOI: 10.1182/blood-2009-03-212282.
15 Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease[J]. Blood, 1995, 86(4): 1261-1268. PMID: 7632930.